Trials / Recruiting
RecruitingNCT06379646
An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
An Exploratory Clinical Study of the Safety and Efficacy of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- Sponsor
- China Immunotech (Beijing) Biotechnology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
An exploratory clinical study of the safety and efficacy of YTS109 cell injection in subjects with recurrent/refractory autoimmune disease
Detailed description
This study is a prospective exploratory clinical trial in subjects with recurrent/refractory autoimmune disease. The objective is to evaluate the safety, initial efficacy and PK/PD characteristics of YTS109 cells in the treatment of recurrent/refractory autoimmune diseases.
Conditions
- Systemic Lupus Erythematosus
- Systemic Sclerosis
- Inflammatory Myopathy
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Antiphospholipid Syndrome
- Sjogren's Syndrome
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | YTS109 | Subjects will receive YTS109 Cell Injection(3E6STAR+T cell/kg) once in this study. |
Timeline
- Start date
- 2024-04-24
- Primary completion
- 2025-04-21
- Completion
- 2026-04-21
- First posted
- 2024-04-23
- Last updated
- 2024-08-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06379646. Inclusion in this directory is not an endorsement.